Clinical trial
A Open Label, Phase II, Non Randomized, Clinical Trial of Chemotherapy Treatment With 5-Azacytidine Plus Valproic Acid and Eventually Atra for Patients Diagnosed With Intermediate II and High Risk Myelodysplastic Syndrome (MDS). EudraCT Number 2005-004811-31. GIMEMA Protocol MDS0205
NCT00439673 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Open Label, Phase II, Non Randomized, Clinical Trial of Chemotherapy Treatment With 5-Azacytidine Plus Valproic Acid and Eventually Atra for Patients Diagnosed With Intermediate II and High Risk Myelodysplastic Syndrome (MDS). EudraCT Number 2005-004811-31. GIMEMA Protocol MDS0205
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2007
- Completion date
- July 31, 2010
- Enrollment
- 62 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.